“…In patient with GACI, mutation in the ENPP1 gene leads to decreased levels of PPi, which is a potent inhibitor of hydroxyapatite-crystal deposition within blood vessel walls [28,30]. 75-80% of affected individuals have mutations in this gene [10,17,18,28].…”